{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:13:51Z","timestamp":1789492431678,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.04.024","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:36:22Z","timestamp":1782992182000},"page":"781-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic therapy for HCC: Doublets, triplets and beyond"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-5538","authenticated-orcid":false,"given":"Arndt","family":"Vogel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1984-2430","authenticated-orcid":false,"given":"Robin Kate","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jhep.2026.04.024_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.jhep.2026.04.024_bib2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib3","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jhep.2026.04.024_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.32723","article-title":"International trends in hepatocellular carcinoma incidence, 1978-2012","volume":"147","author":"Petrick","year":"2020","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.jhep.2026.04.024_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","article-title":"Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study","volume":"69","author":"Romano","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib6","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.31267","article-title":"Comparative effectiveness of entecavir versus tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"73","author":"Dave","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2026.04.024_bib7","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jhep.2026.04.024_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-year outcomes of the national hepatitis B immunization program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2026.04.024_bib10","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"20","key":"10.1016\/j.jhep.2026.04.024_bib11","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jhep.2026.04.024_bib12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","article-title":"Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"35","author":"Sangro","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jhep.2026.04.024_bib13","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"12","key":"10.1016\/j.jhep.2026.04.024_bib14","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10492","key":"10.1016\/j.jhep.2026.04.024_bib15","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jhep.2026.04.024_bib16","article-title":"Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab\/bevacizumab","volume":"7","author":"Wu","year":"2025","journal-title":"JHEP Rep"},{"issue":"10","key":"10.1016\/j.jhep.2026.04.024_bib17","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/jgh.13761","article-title":"Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma: experience from a German referral center","volume":"32","author":"Kirstein","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.04.024_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221080298","article-title":"Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience","volume":"14","author":"de Castro","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"10.1016\/j.jhep.2026.04.024_bib19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial","volume":"22","author":"Galle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jhep.2026.04.024_bib20","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10408","key":"10.1016\/j.jhep.2026.04.024_bib21","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jhep.2026.04.024_bib22","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S1470-2045(25)00543-1","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study","volume":"26","author":"Qin","year":"2025","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2026.04.024_bib23","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jhep.2025.03.033","article-title":"Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC","volume":"83","author":"Rimassa","year":"2025","journal-title":"J Hepatol"},{"issue":"23","key":"10.1016\/j.jhep.2026.04.024_bib24","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.23.01462","article-title":"Patient-reported outcomes from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"42","author":"Sangro","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.04.024_bib25","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.annonc.2025.05.161","article-title":"148O Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d\/c) due to treatment-related adverse events (TRAEs): results from CheckMate 9DW","volume":"36","author":"Sangro","year":"2025","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jhep.2026.04.024_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jhep.2026.04.024_bib28","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jhep.2026.04.024_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jhep.2026.04.024_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"issue":"15","key":"10.1016\/j.jhep.2026.04.024_bib31","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jhep.2026.04.024_bib32","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jhep.2024.12.016","article-title":"Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma","volume":"82","author":"Cappuyns","year":"2025","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2026.04.024_bib33","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1200\/JCO.22.00972","article-title":"Nivolumab plus cabozantinib with or without ipilimumab for advanced hepatocellular carcinoma: results from cohort 6 of the CheckMate 040 trial","volume":"41","author":"Yau","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.04.024_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.08.2101","article-title":"1471MO Adding ipilimumab (IPI) to atezolizumab (ATEZO) plus bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81\/FFCD 2101 - triplet HCC","volume":"36","author":"Merle","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.04.024_bib35","article-title":"LBA50 IMbrave152\/SKYSCRAPER-14: a phase III study of first-line tiragolumab (tira) + atezolizumab (atezo) + bevacizumab (bev) vs placebo (pbo) + atezo + bev for patients (pts) with untreated locally advanced or metastatic hepatocellular carcinoma (HCC)","volume":"36","author":"Finn","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jhep.2026.04.024_bib36","article-title":"Harnessing vaccines in the treatment of solid tumors: advances, challenges, and future directions","volume":"14","author":"Iranzo","year":"2026","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib37","article-title":"Cell surface proteins in hepatocellular carcinoma: from Bench to Bedside","volume":"8","author":"Siracusano","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"10.1016\/j.jhep.2026.04.024_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.114203","article-title":"Advances in the clinical application of bispecific antibodies in cancer therapy","volume":"28","author":"Zhou","year":"2025","journal-title":"iScience"},{"issue":"24","key":"10.1016\/j.jhep.2026.04.024_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71432","article-title":"The landscape of bispecific antibodies in solid tumor oncology: trends, challenges, and Opportunities","volume":"14","author":"ElBeblawy","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.jhep.2026.04.024_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1599181","article-title":"Unlocking new horizons in oncology: ivonescimab's dual-target approach to anti-VEGF\/PD-1(L1) therapy","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2026.04.024_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1431211","article-title":"Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy","volume":"15","author":"Du","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhep.2026.04.024_bib42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/JHC.S456683","article-title":"CRISPR in targeted therapy and adoptive T cell immunotherapy for hepatocellular carcinoma","volume":"11","author":"Palaz","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"issue":"2","key":"10.1016\/j.jhep.2026.04.024_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020271","article-title":"Adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase clinical trials","volume":"13","author":"Rochigneux","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhep.2026.04.024_bib44","article-title":"GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma","volume":"39","author":"Guan","year":"2024","journal-title":"Biochem Biophys Rep"},{"issue":"4","key":"10.1016\/j.jhep.2026.04.024_bib45","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/imm.13677","article-title":"Application of adoptive cell therapy in hepatocellular carcinoma","volume":"170","author":"Wu","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.jhep.2026.04.024_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.879452","article-title":"A phase I study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma","volume":"13","author":"Bae","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jhep.2026.04.024_bib47","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.jhep.2025.06.007","article-title":"Chimeric antigen receptor (CAR) T-cell therapy: engineering immune cells to treat liver diseases","volume":"83","author":"Jaeckel","year":"2025","journal-title":"J Hepatol"},{"issue":"15","key":"10.1016\/j.jhep.2026.04.024_bib48","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib49","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib50","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jhep.2025.07.033","article-title":"Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma","volume":"84","author":"Meyer","year":"2026","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib51","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/gutjnl-2021-325918","article-title":"Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification","volume":"72","author":"Montironi","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41392-025-02343-3","article-title":"Oncolytic viruses: advanced strategies in cancer therapy","volume":"11","author":"Xiao","year":"2026","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"10.1016\/j.jhep.2026.04.024_bib53","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1615817","article-title":"Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)","volume":"8","author":"Moehler","year":"2019","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.jhep.2026.04.024_bib54","first-page":"CD013731","article-title":"Gene therapy for people with hepatocellular carcinoma","volume":"6","author":"Naing","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.jhep.2026.04.024_bib55","article-title":"A comprehensive review on cancer vaccines and vaccine strategies in hepatocellular carcinoma","volume":"11","author":"Tojjari","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.jhep.2026.04.024_bib56","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/2326-6066.CIR-21-0931","article-title":"Combination neoantigen-based dendritic cell vaccination and adoptive T-cell transfer induces antitumor responses against recurrence of hepatocellular carcinoma","volume":"10","author":"Peng","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"10.1016\/j.jhep.2026.04.024_bib57","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jhep.2026.04.024_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25122861","article-title":"Antibody-drug conjugates and targeted treatment strategies for hepatocellular carcinoma: a drug-delivery perspective","volume":"25","author":"Dahlgren","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.jhep.2026.04.024_bib59","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.jhep.2026.04.024_bib60","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s12033-023-00737-8","article-title":"Advantages of material biofunctionalization using nucleic acid aptamers in tissue engineering and regenerative medicine","volume":"65","author":"Abpeikar","year":"2023","journal-title":"Mol Biotechnol"},{"key":"10.1016\/j.jhep.2026.04.024_bib61","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.omtn.2018.09.013","article-title":"Phosphorothioate-modified AP613-1 specifically targets GPC3 when used for hepatocellular carcinoma cell imaging","volume":"13","author":"Dong","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"issue":"10","key":"10.1016\/j.jhep.2026.04.024_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12100985","article-title":"Targeted therapy of hepatocellular carcinoma using gemcitabine-incorporated GPC3 aptamer","volume":"12","author":"Park","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.seminoncol.2025.152434","article-title":"Nanoparticle-based approaches for doxorubicin delivery in hepatocellular carcinoma: current strategies and emerging innovations","volume":"53","author":"Alkhathami","year":"2026","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.jhep.2026.04.024_bib64","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/d41573-025-00096-w","article-title":"The landscape for radioligand therapies in oncology","volume":"24","author":"To","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jhep.2026.04.024_bib65","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2025.09.004","article-title":"Glypican-3: novel theranostic agent for hepatocellular carcinoma","author":"Filippi","year":"2025","journal-title":"Semin Nucl Med"},{"issue":"10504","key":"10.1016\/j.jhep.2026.04.024_bib66","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0140-6736(25)01042-6","article-title":"The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment","volume":"406","author":"Chan","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jhep.2026.04.024_bib67","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat Cancer"},{"issue":"9","key":"10.1016\/j.jhep.2026.04.024_bib68","doi-asserted-by":"crossref","DOI":"10.4251\/wjgo.v17.i9.108649","article-title":"Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: from oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma","volume":"17","author":"Zhan","year":"2025","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib69","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13046-022-02383-5","article-title":"A first-in-human phase 1\/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors","volume":"41","author":"Chan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jhep.2026.04.024_bib70","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-Human phase I study of Fisogatinib (BLU-554) Validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.jhep.2026.04.024_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105893","article-title":"E7386 in patients with advanced solid tumors: results from the dose-escalation part and an expansion part of a phase I study","volume":"10","author":"Kondo","year":"2025","journal-title":"ESMO Open"},{"issue":"23","key":"10.1016\/j.jhep.2026.04.024_bib72","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-25-0725","article-title":"E7386 enhances Lenvatinib's antitumor activity in Preclinical models and human hepatocellular carcinoma","volume":"31","author":"Mesropian","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jhep.2026.04.024_bib73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1124\/jpet.121.000634","article-title":"The small molecule BC-2059 inhibits Wingless\/Integrated (Wnt)-Dependent gene transcription in cancer through Disruption of the Transducin beta-like 1-beta-Catenin protein complex","volume":"378","author":"Soldi","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.jhep.2026.04.024_bib74","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41416-021-01260-w","article-title":"Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab","volume":"124","author":"Zhu","year":"2021","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.jhep.2026.04.024_bib75","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/sj.bjc.6605017","article-title":"Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis","volume":"100","author":"Schoenleber","year":"2009","journal-title":"Br J Cancer"},{"issue":"19","key":"10.1016\/j.jhep.2026.04.024_bib76","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1158\/1078-0432.CCR-15-2883","article-title":"Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib with or without Erlotinib in the SEARCH trial","volume":"22","author":"Zhu","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jhep.2026.04.024_bib77","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1053\/j.gastro.2019.01.261","article-title":"Biomarkers associated with response to Regorafenib in patients with hepatocellular carcinoma","volume":"156","author":"Teufel","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2026.04.024_bib78","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jhep.2016.04.015","article-title":"Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma","volume":"65","author":"Zhu","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib79","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000519867","article-title":"Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma","volume":"11","author":"Rimassa","year":"2022","journal-title":"Liver Cancer"},{"issue":"27","key":"10.1016\/j.jhep.2026.04.024_bib80","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1038\/s41388-018-0206-3","article-title":"A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma","volume":"37","author":"Labgaa","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib81","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41388-020-01519-1","article-title":"Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma","volume":"40","author":"von Felden","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2026.04.024_bib82","article-title":"Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer","author":"von Felden","year":"2021","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.jhep.2026.04.024_bib83","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer Genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jhep.2026.04.024_bib84","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2017.05.014","article-title":"Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification","volume":"67","author":"Calderaro","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib85","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib86","doi-asserted-by":"crossref","first-page":"7477","DOI":"10.1038\/s41467-022-35144-1","article-title":"Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers","volume":"13","author":"Hsiehchen","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jhep.2026.04.024_bib87","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/gutjnl-2024-331956","article-title":"Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments","volume":"73","author":"Campani","year":"2024","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jhep.2026.04.024_bib88","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/1078-0432.CCR-24-1897","article-title":"Personalized MRD assessment in Perisurgical ctDNA for prognostic prediction in hepatocellular carcinoma","volume":"31","author":"Hu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib89","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3233\/CBM-230431","article-title":"Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab","volume":"41","author":"Mohamed","year":"2024","journal-title":"Cancer Biomark"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib90","article-title":"Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis","volume":"3","author":"Sun","year":"2024","journal-title":"BMJ Oncol"},{"key":"10.1016\/j.jhep.2026.04.024_bib91","doi-asserted-by":"crossref","DOI":"10.1159\/000549565","article-title":"Clinical feasibility of circulating tumor DNA in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab","author":"Hwang","year":"2025","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2026.04.024_bib92","article-title":"Feasibility of Personalized and tumor-informed circulating tumor DNA assay for early recurrence detection in patients with hepatocellular carcinoma","volume":"9","author":"Abdelrahim","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2026.04.024_bib93","doi-asserted-by":"crossref","DOI":"10.1200\/PO-25-00621","article-title":"Bespoke circulating tumor DNA testing for diagnostic Resolution, disease Surveillance, and treatment monitoring in Hepatopancreatobiliary malignancies: a real-world experience","volume":"10","author":"Abidoye","year":"2026","journal-title":"JCO Precis Oncol"},{"issue":"18","key":"10.1016\/j.jhep.2026.04.024_bib94","doi-asserted-by":"crossref","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","article-title":"Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma","volume":"69","author":"Hoshida","year":"2009","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.jhep.2026.04.024_bib95","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1158\/0008-5472.CAN-08-0742","article-title":"Focal gains of VEGFA and molecular classification of hepatocellular carcinoma","volume":"68","author":"Chiang","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jhep.2026.04.024_bib96","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.21467","article-title":"Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets","volume":"45","author":"Boyault","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2026.04.024_bib97","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","article-title":"Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis","volume":"75","author":"Pinyol","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.04.024_bib98","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","article-title":"Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial","volume":"68","author":"Pinyol","year":"2019","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.jhep.2026.04.024_bib99","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.04.024_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102473","article-title":"Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"issue":"4","key":"10.1016\/j.jhep.2026.04.024_bib101","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/1078-0432.CCR-25-1592","article-title":"T-cell receptor and immune gene expression Pharmacodynamics for durvalumab alone and with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma","volume":"32","author":"Kelley","year":"2026","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.jhep.2026.04.024_bib102","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/S1470-2045(23)00468-0","article-title":"Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study","volume":"24","author":"Zeng","year":"2023","journal-title":"Lancet Oncol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826002278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826002278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:54:05Z","timestamp":1789491245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826002278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0168827826002278"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.04.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic therapy for HCC: Doublets, triplets and beyond","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}